Merck Closes $1.1B Sirna Acquisition After RNAi Shop Tentatively Settles Three Lawsuits

The firms closed the deal after Sirna was able to tentatively settle a trio of shareholder-led lawsuits seeking to block the acquisition. The suits accused Sirna brass of double-dealing in their negotiations with Merck.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.